Interventional Pain Procedures: A Narrative Review Focusing on Safety and Complications. Part 4 — Peripheral Nerve, Joint, Musculoskeletal, and Regenerative Interventions Authors: Giuliano Lo Bianco, Ezio Amorizzo, Felice Occhigrossi, Marco Mercieri, Sudhir Diwan, Miles Day, Maurizio Marchesini, Emanuele Piraccini, Annu H Navani, Douglas P Beall, Philippe Mavrocordatos, Ali Valimahomed, Timothy R Deer, Alaa Abd-Elsayed Published: 2026 ABSTRACT AbstractThe first three installments of this series examined the safety and complications of injections for spinal pain (Part 1), interventional procedures for back pain (Part 2), and sympathetic and ganglion-targeted techniques (Part 3). This fourth and concluding article addresses the interventions performed away from the neuraxis and the sympathetic chain, which together account for much of everyday pain practice: peripheral and cranial nerve procedures (blocks, chemical neurolysis, radiofrequency, cryoneurolysis, and peripheral or occipital nerve stimulation); joint, bursal, and tendon injections; regenerative or orthobiologic injections; chemodenervation with botulinum toxin; sacroiliac and musculoskeletal soft-tissue procedures; interventions for painful neuroma; and percutaneous ablation of painful bone metastases. Each family carries a characteristic and occasionally serious spectrum of adverse events: local-anesthetic systemic toxicity, pneumothorax, and nerve injury with peripheral and truncal blocks; post-procedural neuritis, thermal injury, and neuroma with radiofrequency and cryoneurolysis; device-related events with peripheral and occipital stimulation; septic arthritis, chondrotoxicity, and the recently recognized structural joint effects of intra-articular corticosteroids; standardization and regulatory concerns with orthobiologics; local weakness, dysphagia, and toxin spread with botulinum toxin; thermal or cryo injury to adjacent structures and pathological fracture with percutaneous ablation of bone metastases; and largely transient events after sacroiliac joint and musculoskeletal soft-tissue procedures. We also address a category common to almost all of these procedures but seldom reviewed: the complications specific to ultrasound guidance itself, chiefly infection from contaminated gel or transducers and the pitfalls of needle-tip visualization. Because most of these targets are superficial and amenable to ultrasound guidance, the reported safety profile is generally favorable; however, this synthesis is narrative and qualitative, and much of the underlying evidence derives from case reports, small series, and heterogeneous cohorts, so a low reported complication burden should not be equated with a precisely established low incidence. As throughout the series, appropriate patient selection, real-time image guidance, aseptic technique, dose and volume limitation, and attention to antithrombotic status are the recurring determinants of safety.Keywords: interventional pain procedures, peripheral nerve block, radiofrequency, orthobiologics, botulinum toxin, ultrasound guidance, complications, safety Introduction This series has sought to provide a practical, complication-oriented map of interventional pain medicine. Part 1 addressed injections for spinal pain,1 Part 2 the broader set of interventional procedures for back pain, including neuromodulation and intrathecal drug delivery,2 and Part 3 the sympathetic- and cranial-ganglion-targeted techniques.3 Those articles cover the axial skeleton and the autonomic nervous system. A substantial and growing part of routine practice, however, is directed at peripheral targets: the peripheral and cranial nerves, the appendicular joints and soft tissues, and, increasingly, biologic and device-based therapies. This concluding installment is devoted to that domain. We organize these procedures into four principal families: peripheral and cranial nerve interventions (blocks, chemical neurolysis, thermal and pulsed radiofrequency, cryoneurolysis, and peripheral or occipital nerve stimulation); joint, bursal, and tendon injections; regenerative or orthobiologic injections; and chemodenervation with botulinum toxin and trigger-point therapy. Most of these targets are superficial, compressible, and visible on ultrasound, which is a genuine technical advantage for avoiding vascular, pleural, and visceral injury; this anatomical accessibility, however, should be distinguished from direct evidence of a low complication incidence, because much of the available literature consists of case reports and small series from which true event rates cannot be derived. Each family nonetheless carries a distinct pattern of adverse events that the proceduralist should anticipate and consent to. We then address several further peripheral procedures, namely sacroiliac and musculoskeletal soft-tissue interventions, treatment of painful neuromas, and percutaneous ablation of painful bone metastases. Because ultrasound underlies almost all of these, we also devote a dedicated section to the complications of ultrasound guidance itself. As in the previous installments, our aim is not to assess efficacy but to provide clinicians with a concise, safety-focused synthesis, drawn from current evidence and reported cases, of the events that may occur and the factors that reduce their likelihood. The specific need this installment addresses is the fragmentation of complication reporting across these heterogeneous peripheral procedures: adverse-event definitions are not standardized, the relevant evidence is dispersed across many small studies, and newer interventions, particularly peripheral neuromodulation and orthobiologics, have entered practice faster than their safety data have accumulated. We restrict inclusion to English-language publications and provide a qualitative rather than a quantitative synthesis. Methods In continuity with Parts 1–3, two authors per topic searched PubMed, Scopus, Embase, and the Cochrane Library for English-language articles published from database inception to 2026, combining terms for each procedure family with “complications” and “safety”. Randomized trials, systematic reviews, observational studies, case series, and case reports describing adverse events were considered. When multiple reports addressed the same intervention, we gave preference to the most recent controlled trials, systematic reviews, and larger observational series, while retaining representative case reports for rare or instructive complications, and where recent evidence from independent groups was available we cited it alongside our own. Where reports were discordant, we gave greater weight to larger or controlled studies and, rather than adjudicating between them, describe the discrepancy and the resulting uncertainty in the text. As a narrative review rather than a systematic review, this article did not follow a PRISMA protocol and was not registered, and no formal risk-of-bias assessment or quantitative pooling was performed; the search and synthesis were structured but non-systematic. Accordingly, numerical complication rates cited from individual studies reflect their original study populations and should not be read as pooled or general incidence estimates, and qualitative descriptors such as “rare” or “low-risk” denote the tenor of the reported literature rather than precisely established rates. Peripheral and Cranial Nerve Blocks and Chemical Neurolysis Peripheral nerve blocks are performed diagnostically and therapeutically throughout the body: in the head and neck (occipital, supraorbital, auriculotemporal), the thorax and abdominal wall (intercostal, erector spinae, pectoral and serratus plane, transversus abdominis plane, ilioinguinal, iliohypogastric, genitofemoral), the pelvis (pudendal), and the limbs (suprascapular, lateral femoral cutaneous). With local anesthetic alone, the adverse events are largely generic to peripheral blockade: local-anesthetic systemic toxicity (LAST) from intravascular injection or cumulative dosing, vasovagal reactions, hematoma, infection, transient unwanted motor block, and needle-related nerve injury or post-block neuritis. Two site-specific hazards deserve emphasis: blocks adjacent to the pleura (intercostal, paravertebral, thoracic wall) carry a small risk of pneumothorax, and deep pelvic or abdominal wall targets carry a risk of visceral or vascular puncture and of enhanced systemic absorption. The mainstays of prevention are ultrasound guidance, careful aspiration and incremental injection, adherence to weight-based local-anesthetic maxima, and immediate availability of a lipid-emulsion rescue protocol for LAST. When durable denervation is sought, chemical neurolysis or radiofrequency may be considered for refractory cases; ultrasound-guided pulsed radiofrequency of the pudendal nerve, for example, has been described for chronic pelvic pain with a low reported complication burden, although the evidence is limited to small series.4 Because chemical neurolysis of mixed peripheral nerves can produce motor deficit, deafferentation pain, and neuritis, sensory targets, low volumes, image confirmation, and non-destructive alternatives are preferred. The relative frequency of these events is procedure-dependent. Intercostal and thoracic-wall blocks carry the highest risk of pneumothorax and, because the intercostal space is highly vascular, among the highest rates of systemic local-anesthetic absorption; abdominal-wall and deep pelvic blocks require particular attention to total dose when performed bilaterally or with large volumes. Direct nerve injury is most often attributable to intraneural or intrafascicular injection, which is signaled by pain or high resistance on injection and is largely preventable by stopping injection if either occurs, using ultrasound to keep the needle tip extraneural, and avoiding dense motor block in awake patients who can report warning symptoms. Peripheral Nerve Radiofrequency, Cooled Radiofrequency, and Cryoneurolysis Conventional, cooled, and pulsed radiofrequency are widely applied to articular sensory branches, most prominently the genicular nerves for knee osteoarthritis, but also the hip articular branches and the intercostal and suprascapular nerves. Reported complications are predominantly local and self-limiting: post-procedural pain, hematoma and ecchymosis, transient paresthesia or hypoesthesia, and, uncommonly, cutaneous thermal injury; clinically significant neurologic deficit is infrequently reported when purely sensory targets and image guidance are used, although this reflects small uncontrolled series rather than robust incidence data.5 Pulsed radiofrequency, a non-destructive alternative that modulates rather than ablates the nerve, is generally regarded as having an especially benign complication profile. Cryoneurolysis produces a reversible axonotmesis that preserves the epineurium, so that return of function is expected over weeks to months. It is generally well tolerated, and both narrative synthesis6 and clinical series of ultrasound-guided genicular cryoanalgesia7 describe a favorable safety profile; the principal concerns are local nerve edema, transient hypoesthesia, and, with superficial targets, depigmentation, dimpling, or alopecia of the overlying skin and, uncommonly, neuroma or post-procedural neuritis. For both modalities, avoidance of mixed-motor nerves, strict sterile technique, adequate skin standoff for cryoprobes, and confirmation of needle or probe position reduce the risk of motor injury and skin complications. Independent reviews echo this profile: a narrative review of genicular radiofrequency ablation described it as effective with a low rate of adverse events,8 and a scoping review of knee cryoneurolysis reported that most complications were mild and self-limiting while cautioning that the technique remains largely investigational.9 Two practical points recur across radiofrequency techniques. First, preservation of motor function depends on lesioning purely sensory branches: sensory–motor stimulation testing before ablation and, where the target lies close to a mixed nerve, the use of pulsed rather than conventional radiofrequency reduces the risk of motor injury. Second, incomplete or short-lived relief, rather than a true complication, is common and partly reflects anatomical variability of the genicular and articular branches; cooled and multi-lesion techniques aim to capture this variability with larger ablation zones, at the cost of slightly longer procedures but without a clear increase in serious adverse events. Peripheral and Occipital Nerve Stimulation Peripheral nerve stimulation (PNS) and occipital nerve stimulation (ONS) extend neuromodulation to peripheral and cranial targets: ONS for refractory chronic cluster headache and occipital neuralgia, percutaneous PNS for focal mononeuropathies and post-surgical pain, and dorsal-root-ganglion stimulation for focal neuropathic pain. Unlike the ablative techniques above, the dominant risks are device- and implant-related: lead migration, hardware malfunction or fracture, infection, skin erosion, and pain at the lead or generator site. In a recent multicenter ONS registry for refractory chronic cluster headache, device-related complications included hardware dysfunction (15%), pain at the insertion site (12.5%), infection (7.5%), and lead migration (5%), the last of which was reduced with dedicated anchoring leads.10 Because these complications overlap substantially with those of spinal cord and dorsal-root-ganglion stimulation and of intrathecal drug delivery, reviewed in detail in Part 2,2 we address here only the features specific to peripheral and cranial placement. Peripheral nerve field stimulation and subcutaneous (peripheral field) stimulation, in which leads are placed in the subcutaneous tissue over the painful region rather than along a named nerve, are used for focal craniofacial and truncal neuropathic pain. Their complication pattern mirrors that of other peripheral stimulation (lead migration, skin erosion, infection, and “pocket pain” at the generator site), with newer partially implantable and wireless systems designed to lower the hardware burden.11 Painful Neuroma and Scar-Related Interventions Painful neuromas, most often iatrogenic and following surgery or amputation, and painful surgical scars are increasingly treated percutaneously when conservative measures fail. Options include local anesthetic and corticosteroid injection, chemical neurolysis with phenol or alcohol, thermal or pulsed radiofrequency, cryoablation, and peripheral nerve stimulation, as illustrated by the range of approaches described for neuroma of the infrapatellar branch of the saphenous nerve after knee surgery.12 The complications are those of the underlying modality: transient post-procedural pain and dysesthesia, local hematoma and infection, skin depigmentation or dimpling after superficial cryoablation, and, paradoxically, the potential for a chemical or thermal lesion to generate a new and sometimes more painful neuroma. Image guidance, conservative lesion size, and a preference for non-destructive options (pulsed radiofrequency, stimulation) in mixed or superficial nerves reduce these risks. Joint, Bursal, and Tendon Injections Intra-articular and peri-articular injections of corticosteroid, with or without local anesthetic, are among the most frequently performed procedures in musculoskeletal and pain practice. Acute complications are usually minor: post-injection flare, vasovagal reactions, transient hyperglycemia, facial flushing, and, with superficial injections, skin hypopigmentation or fat atrophy. Septic arthritis is the most feared infectious complication but is rare; in a large propensity-matched analysis, large-joint corticosteroid injection did not increase the absolute risk of septic arthritis (on the order of 0.1–0.2%), reinforcing that, with aseptic technique, the procedure is safe in this respect.13 Two pharmacologic risks warrant particular attention. First, local anesthetics are chondrotoxic in vitro and in animal models, especially at higher concentrations and with prolonged intra-articular exposure. However, clinical chondrolysis after single or intermittent injections appears uncommon.14 Second, and more recently characterized, intra-articular corticosteroid injection has been associated with adverse structural joint events (accelerated osteoarthritis progression, subchondral insufficiency fracture, osteonecrosis, and rapid joint destruction), prompting cautious use, explicit consent, and attention to joints at risk.15 Peri-tendinous corticosteroid injection can also weaken tendons and, uncommonly, precipitate rupture. Limiting injection frequency, avoiding intratendinous deposition, and confirming the target with ultrasound are prudent measures. Several practical implications follow. The frequency of intra-articular corticosteroid injection is commonly limited to no more than three to four times per year in a given joint, and the newly recognized structural joint risks should be discussed as part of informed consent, particularly in patients with advanced osteoarthritis, subchondral marrow lesions, or acute pain out of proportion to imaging. Viscosupplementation is generally well tolerated but can occasionally provoke an acute pseudoseptic inflammatory reaction, especially with cross-linked hyaluronic acid, which must be distinguished from true infection. Sacroiliac Joint and Posterior Pelvic Interventions Sacroiliac joint (SIJ) pain is commonly managed with intra-articular corticosteroid injection and, for more durable relief, radiofrequency ablation of the sacral lateral branches. Intra-articular injection shares the general risks of joint injection (flare, vasovagal reaction, and infection), with the added consideration that the ventral joint lies close to the L5 and sacral nerve roots and pelvic vessels, giving a small risk of inadvertent neural or vascular spread. Lateral-branch radiofrequency is generally well tolerated: in a large series of combined sensory-branch and dorsal-root radiofrequency for SIJ pain, complications were limited to transient soreness, bruising, tenderness, myofascial pain, and occasional vasovagal responses, without lasting sequelae.16 The marked anatomical variability of the sacral lateral branches explains much of the incomplete relief seen with these procedures and has driven the use of multi-lesion and cooled techniques; image guidance and sensory stimulation before ablation reduce the risk of injury to adjacent neural structures. Musculoskeletal Soft-Tissue Procedures: Hydrodilatation, Barbotage, and Tendon Interventions Several soft-tissue procedures round out the peripheral pain practice. Hydrodilatation (capsular distension) with corticosteroid and saline is used for adhesive capsulitis of the shoulder; reported adverse events are generally minor, the main ones being injection pain, vasovagal reactions, transient post-injection discomfort, and, inherent to the technique, capsular rupture, which is usually clinically inconsequential.17 Ultrasound-guided percutaneous needling and lavage (barbotage) for rotator cuff calcific tendinitis is likewise reported to be safe and effective, with adverse events largely limited to transient post-procedural pain and, uncommonly, a self-limiting bursitis, and with no clear difference in complication rates among minimally invasive techniques.18 Plantar-fascia and greater-trochanteric (gluteal tendinopathy) injections carry the same generic risks plus, when corticosteroid is used, the modality-specific concerns of fat-pad atrophy, skin depigmentation, and, with repeated or intratendinous injection, tendon or fascial weakening and rupture. Limiting corticosteroid frequency, avoiding intratendinous deposition, and confirming placement with ultrasound are the relevant safeguards. Regenerative and Orthobiologic Injections Orthobiologic injections, including platelet-rich plasma (PRP), bone marrow aspirate concentrate, adipose-derived products, and prolotherapy, are increasingly used to treat osteoarthritis and tendinopathy. Their procedure-related safety profile is generally favorable: the most frequent events are transient post-injection pain, swelling, and stiffness, with low rates of infection when aseptic technique is observed, and syntheses of PRP for knee osteoarthritis report few serious adverse events.19 The principal concerns are less about acute harm than about heterogeneity and oversight: preparations vary widely in platelet and leukocyte content, activation, and dosing; the evidence for durable benefit is inconsistent; and regulatory frameworks differ markedly across jurisdictions. Transparent characterization of the injectate, standardized preparation, realistic consent, and regulatory compliance are the relevant safeguards. Chemodenervation with Botulinum Toxin Botulinum toxin is used for chronic migraine, cervical dystonia–associated pain, spasticity, and refractory myofascial and regional pain.20 It is generally well tolerated; the common adverse events are injection-site and neck pain, transient dose-dependent local muscle weakness, ptosis and facial asymmetry, and, with cervical injection, dysphagia. Technical factors, including injection depth and needle length, influence local adverse events such as neck pain.21 Rare but important concerns are distant spread of toxin effect and immunogenicity with neutralizing-antibody formation and secondary non-response. Using the lowest effective dose, anatomically precise (ultrasound- or EMG-guided) placement, and the longest reasonable inter-treatment interval mitigates these risks. Trigger-Point and Myofascial Injections Trigger-point injection and dry needling for myofascial pain are low-risk but not risk-free. Reported complications include vasovagal reactions, local hematoma and soreness, skin infection, and, for thoracic and periscapular targets, pneumothorax. Rarely, deep or blind paraspinal needling has caused direct neural injury, including an isolated report of needle-induced spinal cord injury,22 reinforcing the value of conservative needle depth, anatomical knowledge, and image guidance for higher-risk locations. Percutaneous Ablation of Painful Bone Metastases and Musculoskeletal Tumors Image-guided percutaneous thermal ablation, comprising radiofrequency, cryoablation, and microwave ablation, often combined with cementoplasty, and, non-invasively, magnetic resonance-guided focused ultrasound, has become an established option for palliation of painful bone metastases and selected benign musculoskeletal tumors, providing pain relief, local tumor control, and prevention of skeletal-related events.23 Because these procedures are usually one component of multidisciplinary cancer-pain management, they are best delivered within a multimodal framework alongside radiotherapy, radiopharmaceuticals, and systemic therapy.24 The principal complications reflect thermal or mechanical injury to structures adjacent to the target: burns or cryo-injury to skin and soft tissue, damage to nearby nerves with motor or sensory deficit, and, near the spine, thermal injury to the cord or roots; other events include post-ablation pain flare, pathological fracture of the treated bone, bleeding, and infection. Prevention relies on precise image guidance, active thermal protection of adjacent structures (thermocouples, hydrodissection, or gas or warm saline insulation, and neural monitoring near the neuraxis), careful case selection, and prophylactic stabilization or cementoplasty where fracture risk is high. Antithrombotic Considerations and General Safety Most peripheral procedures involve superficial, compressible sites and are therefore categorized as low bleeding-risk, for which routine interruption of antithrombotic therapy is often unnecessary; deeper or non-compressible targets warrant individualized assessment in line with current ASRA Pain Medicine recommendations.25 Aseptic technique, aspiration before injection, dose and volume limitation, preparedness for LAST, and clear documentation and transparent reporting of adverse events remain the common denominators of safe practice. Figure 1 summarizes this cross-cutting safety workflow, which applies across the procedure families reviewed here. Cross-cutting safety workflow for peripheral interventional pain procedures, from patient selection and antithrombotic assessment through asepsis and ultrasound infection control, real-time image guidance, modality-specific safeguards, monitoring and rescue, and transparent adverse-event reporting. The modality-specific branches cover the procedure families reviewed; the safeguards listed within each branch are representative rather than exhaustive. Abbreviations: ASRA, American Society of Regional Anesthesia and Pain Medicine; EMG, electromyography; LAST, local-anesthetic systemic toxicity; RF, radiofrequency; US, ultrasound. Ultrasound-Related Complications and Infection Control Because ultrasound has become the default guidance modality for most procedures, the safety of ultrasound warrants specific comment. Diagnostic ultrasound uses no ionizing radiation, and at diagnostic acoustic outputs, its thermal and mechanical bioeffects are negligible; the procedure-specific hazards of ultrasound therefore relate not to the acoustic energy but to infection control and to the pitfalls of image interpretation. The two tangible infectious risks are the coupling gel and the transducer. Ultrasound gel, particularly from multi-use containers that are topped up rather than replaced, can become intrinsically or extrinsically contaminated and has been implicated as a source of Burkholderia cepacia complex and Pseudomonas, with documented outbreaks of gel- and device-associated infection;26 for any procedure that breaches the skin, sterile single-use gel should be used. Figure 2 summarizes the hazards specific to ultrasound guidance and the corresponding safeguards. Ultrasound-guided needling: technique, pitfalls, and needle–tissue interaction. Left, in-plane technique with an intact sterile barrier: a sterile probe sheath and sterile single-use gel separate the transducer from the procedural field, and a shallow insertion angle keeps the needle within the scan plane so that the tip is continuously visualized at the target. Right, two common pitfalls: in an out-of-plane approach the bright dot seen within the scan plane is the needle shaft rather than the tip, whose true position lies beyond the plane; and at steep insertion angles specular reflection is directed away from the transducer, reducing tip conspicuity. Bottom, needle–tissue and needle–nerve interaction: mechanical contact with the nerve and the injection technique determine the force and pressure transmitted to the target, with bolus injection producing higher, transient pressure peaks than continuous infusion, so that intraneural or intrafascicular placement may not be recognized from the image alone. The diagram is a schematic orientation aid and is not drawn to scale. Arrow and line conventions: coloured leader arrows identify the labelled features, teal indicating the sterile barrier (probe sheath and coupling gel), green indicating correct needle-tip visualization, and red indicating hazards and pitfalls. Needles are drawn as solid dark lines where they lie within the scan plane and as a dashed grey line where the needle continues beyond the scan plane and is therefore not imaged. The short dashed grey arrows in the right-hand panel indicate the direction of specular reflection away from the transducer at steep insertion angles, and the small red arrow in the lower panel indicates the force transmitted at the point of needle–nerve contact. The transducer is likewise a potential fomite. Probes that are not adequately reprocessed can transmit bacteria, fungi, and viruses (including blood-borne and human papillomavirus) between patients; under the Spaulding classification, transducers contacting intact skin are non-critical and require low-level disinfection, whereas those contacting mucosa (endocavity probes) are semi-critical and require high-level disinfection, and any probe used to guide a percutaneous procedure should be covered with a sterile sheath.27 Non-probe surfaces (the cable, keyboard, and console) are frequently overlooked reservoirs and should also be cleaned between patients. Because infection-control recommendations for ultrasound-guided procedures are not fully harmonized across specialties and professional societies, proceduralists should be familiar with the standards applicable to their setting.28 For interventional pain procedures specifically, the practical safeguards are a sterile probe cover, sterile gel, skin antisepsis, and care to keep the probe, cord, and cable off the sterile field. Two further non-infectious issues are worth noting. First, contact dermatitis or allergic reactions to coupling gel or to skin antiseptics occur occasionally and are usually self-limiting. Second, and more important clinically, ultrasound is operator-dependent: incomplete visualization or misidentification of the needle tip (mistaking the shaft for the tip, or losing the tip in an off-plane approach) and misinterpretation of artifacts (anisotropy, reverberation, beam-width) can lead to inadvertent vascular, pleural, or neural injury or to injection at the wrong site. Continuous tip visualization, an in-plane technique where feasible, hydrolocation to confirm needle position, and awareness of common artifacts are the principal safeguards, underscoring that image guidance reduces but does not eliminate the need for sound anatomical knowledge and technique. Needle-tip localization deserves particular emphasis, because it is influenced not only by continuous visualization but also by the insertion angle and by the interaction between the needle and the surrounding tissue; steeper angles and specular reflection reduce tip conspicuity, and experimental work has explored signal-processing and driving-voltage strategies to improve needle-tip detection across insertion angles.29 In peripheral nerve procedures, mechanical needle–nerve contact and the injection technique also matter: the force and pressure transmitted to the target tissue differ between bolus injection and continuous infusion, with potential implications for nerve injury and for recognizing intraneural placement.30 These factors reinforce that ultrasound reduces but does not eliminate the need for deliberate needle handling, low injection pressures, and prompt cessation if unexpected resistance or pain occurs. Discussion The procedures reviewed here complete the four-part safety framework of this series, extending it from the neuraxis (Parts 1–2) and the sympathetic and cranial ganglia (Part 3) to the peripheral nerves, joints, soft tissues, and biologic and device-based therapies that make up much of routine pain practice. Three themes recur. First, anatomy drives risk: because most peripheral targets are superficial and compressible, the reported complication burden appears favorable, and ultrasound guidance further reduces vascular, pleural, and visceral injury, although this apparent favorability rests largely on observational data and should not be equated with a precisely established low incidence, and ultrasound introduces its own infection-control and image-interpretation considerations. Second, the nature of the risk varies by modality, being pharmacologic for injectables, thermal or neurodestructive for radiofrequency and neurolysis, and hardware-related for stimulation, so safe practice requires modality-specific anticipation rather than a single generic checklist. Third, two clinical areas warrant particular vigilance: the newly characterized structural joint risks of intra-articular corticosteroids, which should temper the frequency of their use, and the rapidly expanding, heterogeneously regulated field of orthobiologics, where the dominant hazard is uncertainty of preparation and benefit rather than acute harm. A distinct contribution of this installment, and of the series as a whole, is the integration into a single safety framework of complications that are usually discussed separately across nerve blocks, radiofrequency and cryoneurolysis, neuromodulation, joint and soft-tissue injections, orthobiologics, and tumor ablation, including the ultrasound-specific hazards that are rarely reviewed alongside the procedures they enable. Prospective registries and standardized reporting, particularly for peripheral neuromodulation, orthobiologics, and ultrasound infection-control practices, would substantially strengthen the evidence base. Table 1 summarizes the procedures reviewed, their principal indications, the most relevant complications, and the corresponding risk-mitigation and safety measures. Table 1Summary of Peripheral, Joint, and Regenerative Interventions: Indications, Complications, and Safety MeasuresProcedureMain IndicationsKey ComplicationsRisk Mitigation and Safety MeasuresPredominant Basis of the Reported Safety EvidencePeripheral/cranial nerve blocksOccipital, intercostal, abdominal-wall, pudendal, LFCN, suprascapular painLAST, nerve injury/neuritis, pneumothorax (thoracic), hematoma, infectionUltrasound guidance; aspiration; incremental dosing; lipid emulsion available; avoid pleuraMainly case reports and small seriesPeripheral RF/cooled RF/cryoneurolysisGenicular (knee OA), hip articular, intercostal, suprascapularNeuritis, hematoma, paresthesia, thermal injury; skin depigmentation and neuroma (cryo)Sensory targets; image confirmation; sterile technique; skin standoff; avoid mixed-motor nervesTrials and reviews for efficacy; safety largely observationalPeripheral/occipital nerve stimulationRefractory occipital neuralgia, cluster headache, focal mononeuropathyLead migration, hardware malfunction, infection, site painAnchored leads; aseptic implantation; see Part 2 for the neuromodulation frameworkRegistry and cohort seriesJoint/bursal/tendon injectionOsteoarthritis and peri-articular pain, bursitisSeptic arthritis (rare), flare, LA chondrotoxicity, accelerated OA / subchondral fracture / osteonecrosis, tendon ruptureAseptic technique; limit frequency/volume; avoid intratendinous deposition; counsel on joint risksLarge matched cohorts and imaging seriesRegenerative/orthobiologicsOsteoarthritis, tendinopathyTransient pain/swelling; low infection risk; preparation heterogeneity; uncertain benefitAseptic technique; standardized preparation; realistic consent; regulatory complianceSyntheses limited by heterogeneous preparationsBotulinum toxin chemodenervationChronic migraine, cervical dystonia, myofascial painLocal weakness, ptosis, neck pain, dysphagia; rare toxin spread; immunogenicityLowest effective dose; precise (US/EMG) placement; longest reasonable intervalGuideline- and trial-basedTrigger-point/dry needlingMyofascial pain syndromeVasovagal, hematoma, infection, pneumothorax; rare neural injuryConservative needle depth; anatomical knowledge; image guidance for high-risk sitesIsolated case reportsSacroiliac joint and posterior pelvicSIJ-mediated low back painFlare, vasovagal, infection; neural/vascular spread at ventral joint; mostly transient after lateral-branch RFImage guidance; sensory stimulation before RF; cooled/multi-lesion for anatomical variabilityPredominantly single-centre seriesMSK soft-tissue (hydrodilatation, barbotage, tendon)Adhesive capsulitis, calcific tendinitis, plantar/gluteal tendinopathyInjection pain, vasovagal, capsular rupture, self-limiting bursitis; corticosteroid fat-pad atrophy / tendon weakeningUltrasound guidance; limit corticosteroid frequency; avoid intratendinous depositionSystematic reviews and technique seriesPainful neuroma/scar interventionsIatrogenic neuroma, painful scarDysesthesia, hematoma, infection, skin changes; risk of new or worse neuromaImage guidance; conservative lesion size; prefer non-destructive options in mixed/superficial nervesSmall series and case reportsPercutaneous tumor/bone-metastasis ablationPainful bone metastases, selected benign tumorsThermal or cryo injury to skin/nerve/cord, post-ablation flare, fracture, bleeding, infectionPrecise guidance; thermal protection and neural monitoring; case selection; stabilization/cementoplastySpecialty reviews and cohort seriesUltrasound guidance (all procedures)Real-time needle guidanceGel/transducer-related infection; needle-tip misidentification and artifact errorsSterile single-use gel and probe cover; probe/console disinfection; continuous tip visualizationOutbreak reports, disinfection standards, experimental studiesNote: The final column indicates the predominant basis of the reported safety evidence and reflects the authors’ qualitative appraisal of the literature reviewed, not a formal risk-of-bias assessment or evidence grading.Abbreviations: EMG, electromyography; LA, local anesthetic; LAST, local-anesthetic systemic toxicity; LFCN, lateral femoral cutaneous nerve; MSK, musculoskeletal; OA, osteoarthritis; RF, radiofrequency; SIJ, sacroiliac joint; US, ultrasound. Summary of Peripheral, Joint, and Regenerative Interventions: Indications, Complications, and Safety Measures Note: The final column indicates the predominant basis of the reported safety evidence and reflects the authors’ qualitative appraisal of the literature reviewed, not a formal risk-of-bias assessment or evidence grading. Abbreviations: EMG, electromyography; LA, local anesthetic; LAST, local-anesthetic systemic toxicity; LFCN, lateral femoral cutaneous nerve; MSK, musculoskeletal; OA, osteoarthritis; RF, radiofrequency; SIJ, sacroiliac joint; US, ultrasound. Limitations Several limitations temper these conclusions. This is a narrative rather than a systematic review: the search was structured but non-systematic, was restricted to English-language publications, and did not include a formal risk-of-bias assessment or quantitative pooling, so the synthesis is qualitative and may be subject to selection and publication bias. Much of the underlying evidence consists of case reports, small case series, and heterogeneous cohorts, and complication definitions and grading are not standardized across studies; therefore, the true incidence of many of the events described here cannot be estimated with precision, and rare but serious complications are likely underreported. Finally, techniques, devices, and, particularly for orthobiologics, regulatory frameworks are evolving rapidly, so the safety profile of some procedures will continue to change. These constraints reinforce the need for prospective registries and for standardized adverse-event reporting, as emphasized throughout this series. Conclusion Peripheral nerve, joint, regenerative, and chemodenervation procedures are performed in very large numbers and have, on the whole, a generally favorable reported safety profile, but a favorable reported profile is not the same as a precisely established low incidence, “low-risk” is not “no-risk”, and even the ultrasound that guides them carries its own often-overlooked infection-control and interpretive hazards. Each family has a characteristic complication profile, and the determinants of safety are the same ones that run through this entire series: careful patient selection, real-time image guidance, aseptic and meticulous technique, dose and volume restraint, attention to antithrombotic status, and honest, procedure-specific informed consent. The principal contribution of this concluding installment is to consolidate these complications, including the ultrasound-specific hazards usually considered in isolation, into a single, complication-oriented reference spanning the spinal, back, sympathetic and ganglionic, and peripheral domains of interventional pain medicine. Use of AI Use of artificial intelligence: the authors used Anthropic Claude (Claude Opus 4, Anthropic PBC, 2026 release) during the preparation of this manuscript. The tool was used to assist with the organization of the retrieved literature, the drafting and structuring of the text, language editing, and the preparation of the figure schematics; it was used in order to improve the clarity, consistency, and readability of a multi-author manuscript forming part of a four-part series. No AI-generated content was accepted without author verification: all statements, data, and interpretations were checked against the primary sources by the authors, and every reference was verified individually against the original publication. The authors confirm the originality and accuracy of all manuscript content and take full responsibility for the integrity of the whole content, including the accuracy of the references. The authors have checked the terms of use of the specific AI tool employed and confirm that its use is compatible with, and suitable for, publication of this article. Data Sharing Statement Data availability: not applicable: no new datasets were generated or analyzed; all data discussed derive from the cited published sources. Ethics and Consent Ethics approval and consent to participate: not applicable: this is a narrative review of previously published literature that did not involve new research on human participants or animals, so institutional review board approval and informed consent were not required. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. No specific funding was received for the preparation of this article. Disclosure Dr Giuliano Lo Bianco has nothing to disclose. Dr Ezio Amorizzo reports honoraria from Boston Scientific; Leadership or fiduciary roles from Secretary, Cofounder, outside the submitted work. Dr Felice Occhigrossi reports grants or contracts from AlfaMed, Boston Scientific, outside the submitted work. Dr Marco Mercieri has nothing to disclose. Dr Sudhir Diwan has nothing to disclose. Dr Miles Day reports expert testimony from Law firms; Meeting/travel support from Multiple societies; Leadership or fiduciary roles from WIP, ASIPP, NANS, outside the submitted work. Dr Maurizio Marchesini reports Grants or contracts from Grunenthal, Abbot, Medtronic; Consulting fees from AMS, TiMed; Honoraria from Gentili, outside the submitted work. Dr Emanuele Piraccini has nothing to disclose. Dr Annu Navani reports data safety/advisory board participation from Semnur Pharaceuticals; Leadership or fiduciary roles from Board of Governers, American Society of Interventional Pain Physicians; Stock or stock options from Semnur Pharmaceuticals, outside the submitted work. Dr Douglas Beall has nothing to disclose. Dr Philippe Mavrocordatos has nothing to disclose. Dr Ali Valimahomed reports consulting fees from NALU, SPR Therapeutics, Biotronik, Boston Scientific, NERVONIK; Honoraria from American Society of Pain and Neuroscience, World Association of Pain Medicine United; Data safety/advisory board participation from NERVONIK, outside the submitted work. Dr Timothy Deer reports consulting fees from Abbott, Saluda, Spinal Simplicity, Painteq, outside the submitted work. Dr Alaa Abd-Elsayed reports Consulting fees from Medronic, Curonix, Vertex, Avanos, Tonix, outside the submitted work. References Associated Data Data Availability Statement Data availability: not applicable: no new datasets were generated or analyzed; all data discussed derive from the cited published sources.